Search Result

Results for "

Aurora B kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (59) Akt (3) Apoptosis (15) Autophagy (8) Bcr-Abl (6) c-Fms (1) c-Kit (1) CDK (3) DNA/RNA Synthesis (1) EGFR (1) FGFR (1) FLT3 (7) GSK-3 (1) HDAC (1) IGF-1R (2) JAK (4) Kinesin (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) Microtubule/Tubulin (1) Mitosis (3) NEKs (2) PDGFR (1) PERK (1) PROTACs (2) Reactive Oxygen Species (ROS) (2) Reference Standards (5) Src (1) STAT (3) Syk (1) TAM Receptor (1) Tie (1) ULK (1) VEGFR (3)
By Research Areas:	Cancer (60) Inflammation/Immunology (1)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Natural
Products

Antibodies

Click Chemistry

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent **aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B**, respectively .

HY-10161

Tozasertib Maximum Cited Publications 16 Publications Verification VX 680; MK-0457	Aurora Kinase Autophagy	Cancer
Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases with K_i**s of 0.6, 18, 4.6 nM, respectively.

HY-14711

Reversine Maximum Cited Publications 16 Publications Verification	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 400, 500 and 400 nM for Aurora* A, Aurora B and Aurora C, respectively.

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and **aurora kinase inhibitor with IC₅₀** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀**s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-137377

TAS-119 1 Publications Verification	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-145601

Tinengotinib TT 00420	Aurora Kinase FGFR VEGFR	Cancer
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting **Aurora A/B (IC₅₀=1.2-3.3 nM), FGFR1/2/3 (IC₅₀=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R*. Tinengotinib blocks Aurora* kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .

HY-116423

JH295	NEKs	Cancer
JH295 is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2** via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-141512

JB170 3 Publications Verification	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora *Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase* .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-122236

UMK57	Mitosis Kinesin Microtubule/Tubulin Aurora Kinase	Cancer
UMK57 is a MCAK activator and kinetochore-microtubule destabilizer. UMK57 enhances MCAK-dependent microtubule depolymerization, increases kinetochore-microtubule turnover, reduces chromosome mis-segregation and lagging chromosomes, and inhibits cancer cell proliferation. UMK57 triggers adaptive resistance in Aurora B cancer cells via reversible Aurora B signaling pathway alterations. UMK57 can be used for the research of solid tumors .

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 310 nM and 240 nM for Aurora* A and Aurora B, respectively .

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-168022

CAM2602 1 Publications Verification	Aurora Kinase	Cancer
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human K_d of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .

HY-103266

TC-A 2317 hydrochloride	Aurora Kinase	Cancer
TC-A 2317 hydrochloride is an orally active **Aurora A kinase inhibitor (K_i*=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora* B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .

HY-175866

Aurora kinase-IN-8	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-8 is a orally active **Aurora kinase** inhibitor. Aurora kinase-IN-8 shows IC₅₀ values of 2.8 and 28.1 nM against **Aurora A kinase and Aurora B kinase*. Aurora* kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective *spleen tyrosine kinase* (SYK) inhibitor with a pIC₅₀** of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-175525

MS44	PROTACs Aurora Kinase	Cancer
MS44 is a potent aurora kinase B (AURKB PROTAC) degrader (DC₅₀ = 103 nM). MS44 effectively degrades AURKB in a time- and ubiquitin-proteasome system (UPS)-dependent manner and is selective for AURKB over AURKA and AURKC. MS44 effectively inhibits the proliferation in multiple cancer cell lines and potently induces G2/M arrest. MS44 can be used for the study of AURKB-dependent tumors (Pink: Target protein ligand (HY-175526); Blue: E3 ligand (HY-112078); Black: Linker; E3 ligand + Linker (HY-132938)) .

HY-123610

BRD-7880	Aurora Kinase	Cancer
BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-175526

Aurora kinase ligand-1	Ligands for Target Protein for PROTAC Aurora Kinase	Cancer
Aurora kinase ligand-1 (Compound I-4) is an Aurora kinase B (AURKB) PROTAC ligand. Aurora kinase ligand-1 can be conjugated with E3 ligase Ligand (HY-112078) and linker to synthesize AURKB PROTAC degrader MS44 (HY-175525). MS44 can be used for cancer research .

HY-13072R

Cenisertib (Standard) AS-703569 (Standard); R-763 (Standard)	Aurora Kinase Bcr-Abl Akt STAT FLT3 Reference Standards	Cancer
Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent *AURKA/B* dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-111506

Aurora inhibitor 1	Aurora Kinase	Cancer
Aurora inhibitor 1 is a potent *Aurora* inhibitor with an IC₅₀ of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively .

HY-122370A

Tripolin B	Aurora Kinase	Cancer
Tripolin B is an ATP-competitive **Aurora kinase inhibitor with IC₅₀** values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of **Aurora kinases with IC₅₀** values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-124330

Tripolin A (E)-Tripolin A	Aurora Kinase	Others
Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive **Aurora A kinase inhibitor, with IC₅₀** values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively .

HY-N3737

Derrone	Aurora Kinase PERK Reactive Oxygen Species (ROS)	Cancer
Derrone, a prenylated isoflavones, is an **Aurora kinase inhibitor, with IC₅₀** values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-121895

BI 831266	Aurora Kinase	Cancer
BI 831266 is a potent and selective inhibitor of Aurora kinase B with antitumor activity .

HY-10057

AT9283 hydrochloride	Aurora Kinase	Cancer
AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I) .

HY-N3634

Corylifol C	EGFR TAM Receptor Tie	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀**s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-116423A

JH295 hydrate	NEKs	Cancer
JH295 hydrate is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2** via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-173499

HLDA-212	Aurora Kinase Apoptosis	Cancer
HLDA-212 (Compound 43) is a bifunctional small molecule targeting HaloTag-tagged protein (Target Protein, TP) and **Aurora kinase A/B (AURKA/B, Effector Protein, EP). HLDA-212 binds to TP and EP to form a stable ternary complex (TP:RIPTAC:EP), inhibiting the cell-survival function of EP and inducing apoptosis in TP-expressing cancer cells. HLDA-212 shows antiproliferative activity (GI₅₀** of 0.011 μM) in 293_HFL cells. HLDA-212 is promising for research of cancers with high TP expression (such as prostate cancer and hematological malignancies) .

HY-150592

Aurora kinase-IN-2	Aurora Kinase	Cancer
Aurora kinase-IN-2 (compound 12Aj) is a potent **Aurora kinase inhibitor with IC₅₀** values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research .

HY-147993

Aurora kinase inhibitor-10	Aurora Kinase	Cancer
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC₅₀ of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .

HY-176191

Aurora kinase-IN-7	Aurora Kinase	Cancer
Aurora kinase-IN-7 (compound 4b) is an orally active and selective AURKB inhibitor. Aurora kinase-IN-7 can be used in the study of aggressive cancers .

HY-15812

XMD-12	Aurora Kinase	Cancer
XMD-12 (compound 1) is an Aurora kinase (Aurora *Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora* A, B, and C kinases, with IC₅₀ values of 5.6, 18.4, and 24.6 nM, respectively .

HY-121998

Binucleine 2	Aurora Kinase	Others
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.

HY-119951

AKI-001	Aurora Kinase	Cancer
AKI-001 is an prototype pentacyclic inhibitor of **aurora kinase with cellular potency of IC₅₀** of less than 100 nM. AKI-001 shows low nanomolar potency against Aurora A and Aurora B enzymes .

HY-10179R

Danusertib (Standard) PHA-739358 (Standard)	Reference Standards Aurora Kinase Autophagy	Cancer
Danusertib (Standard) is the analytical standard of Danusertib. This product is intended for research and analytical applications. Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-123279

OM137	Aurora Kinase CDK	Cancer
OM137 is an **aurora kinase** inhibitor, with an IC₅₀ of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC₅₀ of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .

HY-19565

KW-2450 tosylate	Aurora Kinase IGF-1R Apoptosis	Cancer
KW-2450 tosylate is an orally active *Aurora* A and B kinases, IGF-1R, and IR tyrosine kinases inhibitor. KW-2450 tosylate induces Apoptosis. KW-2450 tosylate also exhibits anticancer activity against triple-negative breast cancer .

Host:	Rabbit (4)
Reactivity:	Human (4)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IP (3) IHC-F (1) WB (4) ELISA (1)
Isotype:	IgG (2) IgG/Kappa (1)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80562

	Aurora B Antibody (YA594) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IP	Human
	Aurora B Antibody (YA594) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

HY-P86439

	Aurora B Antibody (YA6131) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Aurora B Antibody (YA6131) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

HY-P85045

	Aurora B Antibody (YA4737) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human
	Aurora B Antibody (YA4737) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Aurora B.

HY-P80562A

	Aurora B Antibody (YA594)(PBS only) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IP	Human
	Aurora B Antibody (YA594) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2** via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2** via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aurora B kinase

Inhibitors & Agonists

NaturalProducts

Antibodies

Click Chemistry

Natural
Products